The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | An update on MRD assessment and novel techniques used in the treatment of hematological malignancies
In this video, Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, shares his insights into the use of various techniques in hematological malignancies and the future of research in this area. First, Dr Roschewski discusses the use of minimal residual disease (MRD) testing in many disease areas, including chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myeloid leukemia (AML), and compares this to the use of MRD testing in lymphoma. Dr Roschewski then summarizes some data that he presented, drawing focus to advances in technology such as ctDNA assays, and ties this together to the use of immunotherapies, including CAR T-cell therapy, and how these advances may provide better outcomes for patients in the future. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
